Merck Inc. said late Tuesday that its drug Keytruda did not reach its goals in a late-stage clinical study for the treatment of bladder cancer. The drug maker said bladder cancer patients given Keytruda in a Phase 3 clinical study did not show a statistically significant improvement in overall survival or progression-free survival compared with patients given standard chemotherapy. Keytruda is already approved to treat several other types of cancer. In 2019, Merck reported Keytruda sales made up $11.08 billion of its $46.84 billion in sales. Merck shares rose 0.3% after hours, following a 0.7% decline to close the regular session at $82.26.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.